Introducing Tralement™, the first and only FDA-approved multi-trace element injection for parenteral nutrition.¹

Traelent™ (trace elements injection 4*, USP) is indicated in adult and pediatric patients weighing at least 10 kg as a source of zinc, copper, manganese and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.²

Each mL of Tralement™ provides zinc 3 mg, copper 0.3 mg, manganese 55 mcg, and selenium 60 mcg. Tralement™ is recommended once daily as part of an intravenous nutrition regimen.

Traelent is recommended only for patients who require supplementation with all four of the individual trace elements (i.e., zinc, copper, manganese and selenium).

**ADULT DOSING**

For adults and pediatric patients weighing at least 50 kg, the recommended dose is 1 mL per day added to parenteral nutrition.²

**PEDIATRIC DOSING**

For pediatric patients weighing 10 kg to 49 kg, the recommended dosage of Tralement™ is based on body weight and ranges from 0.2 to 0.8 mL per day.² (refer to table below)

**SUPPLEMENTATION WITH INDIVIDUAL TRACE ELEMENTS†**

For pediatric patients weighing 10 kg to 49 kg, additional zinc, copper and selenium may be required to meet the recommended daily dose (shown below). To determine the additional amount of supplementation, compare the recommended daily dosage based on the body weight of the patient to the amount of each trace element provided by Tralement™ and other dietary resources.²

- Zinc: 50 mcg/kg/day (up to 3,000 mcg/day)
- Copper: 20 mcg/kg/day (up to 300 mcg/day)
- Selenium: 2 mcg/kg/day (up to 60 mcg/day)

†Do not supplement Tralement™ with additional manganese.

<table>
<thead>
<tr>
<th>Patient Population</th>
<th>Body Weight</th>
<th>Tralement™ Dosage (mL)</th>
<th>Zinc</th>
<th>Copper</th>
<th>Manganese</th>
<th>Selenium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pediatric</td>
<td>10 kg to 19 kg</td>
<td>0.2 mL</td>
<td>600 mcg</td>
<td>60 mcg</td>
<td>11 mcg</td>
<td>12 mcg</td>
</tr>
<tr>
<td>Pediatric</td>
<td>20 kg to 29 kg</td>
<td>0.4 mL</td>
<td>1200 mcg</td>
<td>120 mcg</td>
<td>22 mcg</td>
<td>24 mcg</td>
</tr>
<tr>
<td>Pediatric</td>
<td>30 kg to 39 kg</td>
<td>0.6 mL</td>
<td>1800 mcg</td>
<td>180 mcg</td>
<td>33 mcg</td>
<td>36 mcg</td>
</tr>
<tr>
<td>Pediatric</td>
<td>40 kg to 49 kg</td>
<td>0.8 mL</td>
<td>2400 mcg</td>
<td>240 mcg</td>
<td>44 mcg</td>
<td>48 mcg</td>
</tr>
<tr>
<td>Adult and Pediatric</td>
<td>More than 49 kg</td>
<td>1 mL</td>
<td>3 mg</td>
<td>0.3 mg</td>
<td>55 mcg</td>
<td>60 mcg</td>
</tr>
</tbody>
</table>

**RECOMMENDED WEIGHT-BASED DAILY DOSAGE OF TRALEMENT™**

**ADDITIONAL DOSAGE AND ADMINISTRATION DETAILS**

- Tralement™, supplied as a 1 mL single dose vial, is not for direct intravenous infusion and may only be added to parenteral nutrition admixtures
- Tralement™ is not approved for pediatric patients weighing less than 10 kg
- Prior to administration of parenteral nutrition solution containing Tralement™, correct severe fluid, electrolyte, and acid-base disorders
- Monitor trace element concentrations in blood during long-term administration of parenteral nutrition

*For complete dosage and administration information and considerations, please refer to the Tralement™ Full Prescribing Information.

**ADDENDUM**

For pediatric patients weighing 10 kg to 49 kg, the recommended dosage of Tralement™ is based on body weight and ranges from 0.2 to 0.8 mL per day.

*Each mL contains zinc 3 mg, copper 0.3 mg, manganese 55 mcg, and selenium 60 mcg.

Tralement™ is a trademark of American Regent, Inc.

Patents pending. PP-TR-US-0029 \ 10/2020
**INDICATIONS AND USAGE**

Tralement™ is indicated in adult and pediatric patients weighing at least 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.

**IMPORTANT SAFETY INFORMATION**

**Important Administration Information**

Tralement is supplied as a single-dose vial for admixture use only. It is not for direct intravenous infusion. Prior to administration, Tralement must be transferred to a separate parenteral nutrition container, diluted and used as an admixture in parenteral nutrition solution.

**Overview of Dosing**

- Prior to administration of parenteral nutrition solution containing Tralement, correct severe fluid, electrolyte, and acid-base disorders.

- The dosage of the final parenteral nutrition solution containing Tralement must be based on the concentrations of all components in the solution, the patient’s clinical condition, nutritional requirements, and the contribution of oral or enteral intake.

Tralement is recommended only for patients who require supplementation with all four of the individual trace elements (i.e., zinc, copper, manganese, and selenium).

See Full Prescribing Information on preparation, administration and dosing.

**CONTRAINDICATIONS**

Tralement is contraindicated in patients with hypersensitivity to zinc or copper.

**WARNINGS AND PRECAUTIONS**

- **Pulmonary Embolism due to Pulmonary Vascular Precipitates:** If signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation.

- **Vein Damage and Thrombosis:** Solutions with osmolarity of 900 mOsmol/L or more must be infused through a central catheter. The primary complication of peripheral access is venous thrombophlebitis.

- **Neurologic Toxicity with Manganese:** Monitor patients receiving long-term parenteral nutrition solutions containing Tralement for neurologic signs and symptoms and routinely monitor whole blood manganese concentrations and liver function tests. Discontinue Tralement and consider brain magnetic resonance imaging (MRI) if toxicity suspected.

- **Hepatic Accumulation of Copper and Manganese:** Assess for development of hepatic or biliary dysfunction. Monitor concentrations of copper and manganese in patients with cholestasis, biliary dysfunction or cirrhosis receiving Tralement long-term.

- **Aluminum Toxicity:** Tralement contains aluminum that may be toxic. Increased risk in patients with renal impairment, including preterm infants.

- **Monitoring and Laboratory Tests:** Monitor blood zinc, copper, manganese, and selenium concentrations, fluid and electrolyte status, serum osmolarity, blood glucose, liver and kidney function, blood count and coagulation parameters.

- **Hypersensitivity Reactions with Zinc and Copper:** If reactions occur, discontinue Tralement and initiate appropriate medical treatment.

**ADVERSE REACTIONS**

The following adverse reactions were identified in clinical studies or post-marketing reports. Given that some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Adverse reactions with other components of parenteral nutrition solutions:

- Pulmonary embolism due to pulmonary vascular precipitates
- Vein damage and thrombosis
- Aluminum toxicity

Adverse reactions with the use of trace elements administered parenterally or by other routes of administration:

- Neurologic toxicity with manganese
- Hepatic accumulation of copper and manganese
- Hypersensitivity reactions with zinc and copper

**USE IN SPECIFIC POPULATIONS**

**Pregnancy - Risk Summary - Deficiency of trace elements**

May result in adverse pregnancy and fetal outcomes.

**Lactation - Risk Summary - Zinc, copper, manganese, and selenium are present in human milk. The developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for Tralement and any potential adverse effects on the breastfed infant from Tralement or from the underlying maternal condition.**

**Pediatric Use - Refer to Full Prescribing Information before dosing. Do not supplement Tralement with additional manganese. Tralement is not approved for use in pediatric patients weighing less than 10 kg.**

**Hepatic Impairment - Hepatic accumulation of copper and manganese have been reported with long-term administration in parenteral nutrition. For patients with cholestasis, biliary dysfunction, or cirrhosis, monitor hepatic and biliary function during long-term administration of Tralement.**

**OVERDOSAGE - There are reports on overdosage in the literature for the individual trace elements. Management of overdosage is supportive care based on presenting signs and symptoms.**

For additional safety information, please see Full Prescribing Information.

You are encouraged to report Adverse Drug Events (ADEs) to American Regent:

Phone: 1-800-734-9236
Email: pv@americanregent.com
Fax: 1-610-650-0170

Adeas may also be reported to the FDA:

1-888-354-9236 or to www.fda.gov/medwatch

Drug Information:

1-888-354-4855
(9:00 am – 5:00 pm Eastern Time, Monday – Friday)

For urgent drug information outside of normal business hours, assistance is available at:

1-877-845-6371

References:
